BRCA2 and pancreatic neoplasm: In contrast to KPC animals (n = 28, T50 = 24.6 weeks), Palb2-KPC, Brca1-KPC or Brca2-KPC respectively developed PDAC with a much shorter pancreatic tumor-free median survival of 10.1, 11.9 and 13.7 weeks, respectively (Fig 2A).